Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients

Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients

Galunisertib (LY2157299) is a selective ATP-mimetic inhibitor of TGF-β receptor (TβR)-I activation currently under clinical investigation in hepatocellular carcinoma (HCC) patients. Our study explored the effects of galunisertib in vitro in HCC cell lines and ex vivo on patient samples. Galunisertib...

Full description

Bibliographic Details
Main Authors: Serova, Maria, Tijeras-Raballand, Annemilaï, Santos, Célia Dos, Albuquerque, Miguel, Paradis, Valerie, Neuzillet, Cindy, Benhadji, Karim A., Raymond, Eric, Faivre, Sandrine, de Gramont, Armand
Format: Online
Language:English
Published: Impact Journals LLC 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673290/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673290/

Similar Items